- Home
- GRO vs CHRS Comparison
GRO vs CHRS Comparison
Compare GRO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRO
- CHRS
- Stock Information
- Founded
- GRO 2006
- CHRS 2010
- Country
- GRO Canada
- CHRS United States
- Employees
- GRO N/A
- CHRS N/A
- Industry
- GRO
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GRO
- CHRS Health Care
- Exchange
- GRO NYSE
- CHRS Nasdaq
- Market Cap
- GRO 95.8M
- CHRS 96.9M
- IPO Year
- GRO 2024
- CHRS 2014
- Fundamental
- Price
- GRO $2.58
- CHRS $1.12
- Analyst Decision
- GRO Strong Buy
- CHRS Strong Buy
- Analyst Count
- GRO 1
- CHRS 4
- Target Price
- GRO $5.50
- CHRS $5.38
- AVG Volume (30 Days)
- GRO 140.5K
- CHRS 2.0M
- Earning Date
- GRO 05-03-2025
- CHRS 05-08-2025
- Dividend Yield
- GRO N/A
- CHRS N/A
- EPS Growth
- GRO N/A
- CHRS N/A
- EPS
- GRO N/A
- CHRS 0.25
- Revenue
- GRO N/A
- CHRS $266,959,999.00
- Revenue This Year
- GRO N/A
- CHRS N/A
- Revenue Next Year
- GRO N/A
- CHRS $9.02
- P/E Ratio
- GRO N/A
- CHRS $4.50
- Revenue Growth
- GRO N/A
- CHRS 3.78
- 52 Week Low
- GRO $2.17
- CHRS $0.66
- 52 Week High
- GRO $15.00
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- GRO N/A
- CHRS 61.92
- Support Level
- GRO N/A
- CHRS $0.72
- Resistance Level
- GRO N/A
- CHRS $1.07
- Average True Range (ATR)
- GRO 0.00
- CHRS 0.10
- MACD
- GRO 0.00
- CHRS 0.04
- Stochastic Oscillator
- GRO 0.00
- CHRS 95.19
About GRO BRAZIL POTASH CORP
Brazil Potash Corp is a mineral exploration and development company with a potash mining project located in the state of Amazonas, Brazil. The company's technical operations are based in Autazes, Amazonas, Brazil, and Belo Horizonte, Minas Gerais, Brazil. The operating activities of the company includes focusing on the extraction and processing of potash ore from underground mine and selling and distributing the processed potash in Brazil.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.